Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists

References

• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–2393. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4–13. Epub 2008/ 01/25. doi:10.1160/TH07-08-0513.
   PubMed Web of Science ®Google Scholar
• McKenzie CG, Guo L, Freedman J, Semple JW. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol 2013;163:10–23. doi:10.1111/bjh.12480.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960–969. Epub 2012/ 06/29. doi:10.1182/blood-2011-12-309153.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol 2010;47:258–265. doi:10.1053/j.seminhematol.2010.03.003.
   PubMed Web of Science ®Google Scholar
• Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2015;2015:237–242. doi:10.1182/asheducation-2015.1.237.
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015;13:457–464. doi:10.1111/jth.12813.
   PubMed Web of Science ®Google Scholar
• Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database. Haematologica 2010;95:1167–1175. Epub 2010/ 02/11. doi:10.3324/haematol.2009.018390.
   PubMed Web of Science ®Google Scholar
• Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, Sorensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2010. 152(3):360–2. Epub 2010/ 10/20.
   Web of Science ®Google Scholar
• Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, De Stefano V, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014;12:1266–1273. doi:10.1111/jth.12636.
   PubMed Web of Science ®Google Scholar
• Norgaard M, Cetin K, Maegbaek ML, Kristensen NR, Ghanima W, Bahmanyar S, Stryker S, Christiansen CF. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol 2015. 174(4):639–42.
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; Group ES. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537–545. doi:10.1182/blood-2012-04-425512.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161:411–423. doi:10.1111/bjh.12260.
   PubMed Web of Science ®Google Scholar
• Karpatkin S. Heterogeneity of human platelets. II. Functional Evidence Suggestive of Young and Old Platelets. J Clin Invest 1969;48:1083–1087.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013;161:706–714. doi:10.1111/bjh.12318.
   PubMed Web of Science ®Google Scholar
• Campello E, Spiezia L, Radu CM, Simioni P. Microparticles as biomarkers of venous thromboembolic events. Biomark Med 2016;10:743–755. doi:10.2217/bmm-2015-0063.
   PubMed Web of Science ®Google Scholar
• Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, Laszlo V, Pallinger E, Pap E, Kittel A, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011;68:2667–2688. doi:10.1007/s00018-011-0689-3.
   PubMed Web of Science ®Google Scholar
• Freyssinet JM, Toti F. Membrane microparticle determination: at least seeing what’s being sized! J Thromb Haemost 2010;8:311–314.
   PubMed Web of Science ®Google Scholar
• Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011;31:15–26. doi:10.1161/ATVBAHA.109.200956.
   PubMed Web of Science ®Google Scholar
• Harrison P, Gardiner C, Sargent IL. Extracellular vesicles in health and disease, 1st ed. New York: Jenny Stanford Publishing; 2014.
   Google Scholar
• Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284–1297. doi:10.1161/CIRCRESAHA.110.233056.
   PubMed Web of Science ®Google Scholar
• Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85:639–646.
   PubMed Web of Science ®Google Scholar
• Ollivier V, Wang J, Manly D, Machlus KR, Wolberg AS, Jandrot-Perrus M, Mackman N. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res 2010;125:90–96. doi:10.1016/j.thromres.2009.03.003.
   PubMed Web of Science ®Google Scholar
• Bidot L, Jy W, Bidot C Jr., Jimenez JJ, Fontana V, Horstman LL, Ahn YS. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost 2008;6:913–919. doi:10.1111/j.1538-7836.2008.02963.x.
   PubMed Web of Science ®Google Scholar
• Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011;9:2251–2261. doi:10.1111/j.1538-7836.2011.04488.x.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4–15. doi:10.1159/000071636.
   PubMed Web of Science ®Google Scholar
• Sewify EM, Sayed D, Abdel Aal RF, Ahmad HM, Abdou MA. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 2013;131:e59–e63. doi:10.1016/j.thromres.2012.11.021.
   PubMed Web of Science ®Google Scholar
• Alvarez Roman MT, Fernandez Bello I, Arias-Salgado EG, Rivas Pollmar MI, Jimenez Yuste V, Martin Salces M, Butta NV. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost 2014;112:65–72. doi:10.1160/TH13-10-0873.
   PubMed Web of Science ®Google Scholar
• Hellum M, Franco-Lie I, Ovstebo R, Hauge T, Henriksson CE. The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls. PLoS One 2017;12:e0184579. doi:10.1371/journal.pone.0184579.
   PubMed Web of Science ®Google Scholar
• Gheldof D, Mullier F, Chatelain B, Dogne JM, Chatelain C. Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. Blood Coagul Fibrinolysis 2013;24:567–572. doi:10.1097/MBC.0b013e328360a56e.
   PubMed Web of Science ®Google Scholar
• Fontana V, Jy W, Ahn ER, Dudkiewicz P, Horstman LL, Duncan R, Ahn YS. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008;122:599–603. doi:10.1016/j.thromres.2007.12.022.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten Years Later. Haematologica 2019. doi:10.3324/haematol.2018.212845.
   PubMed Web of Science ®Google Scholar
• Justo Sanz R, Monzon Manzano E, Fernandez Bello I, Teresa Alvarez Roman M, Martin Salces M, Rivas Pollmar MI, Jimenez Yuste V, Butta NV. Platelet apoptosis and PAI-1 are involved in the pro-coagulant state of immune thrombocytopaenia patients treated with thrombopoietin receptor agonists. Thromb Haemost 2019. 119(4):645–659.
   PubMed Web of Science ®Google Scholar
• Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 2010;125(Suppl 1):S46–S48. doi:10.1016/j.thromres.2010.01.036.
   PubMedGoogle Scholar
• Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992;12:1111–1121. doi:10.1161/01.ATV.12.10.1111.
   PubMed Web of Science ®Google Scholar
• Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004;104:3190–3197. doi:10.1182/blood-2004-03-0935.
   PubMed Web of Science ®Google Scholar
• Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012;10:1355–1362. doi:10.1111/j.1538-7836.2012.04758.x.
   PubMed Web of Science ®Google Scholar
• Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015;126:1379–1389. doi:10.1182/blood-2015-01-622811.
   PubMed Web of Science ®Google Scholar
• Garabet L, Ghanima W, Monceyron Jonassen C, Skov V, Holst R, Mowinckel MC, Hasselbalch HC, Kruse TA, Thomassen M, Liebman H, et al. Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets 2017.30(2):206–212.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ. New thrombopoietic agents: introduction. Semin Hematol 2010;47:211. Epub 2010/ 07/14. doi:10.1053/j.seminhematol.2010.05.001.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010;47:243–248. Epub 2010/ 07/14. doi:10.1053/j.seminhematol.2010.02.005.
   PubMed Web of Science ®Google Scholar
• Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016;62:699–707. doi:10.1373/clinchem.2015.248625.
   PubMed Web of Science ®Google Scholar
• Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F; The ISSCW. Standardization of pre-analytical variables in plasma microparticle determination: results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost 2013;11:1190–1193. doi:10.1111/jth.2013.11.issue-6.
   Web of Science ®Google Scholar